Merck & Co. announced a breakthrough in manufacturing its investigational oral cholesterol drug, enlicitide decanoate, in a paper published in Science, adding to a pipeline that has seen its stock gain 34 percent in six months.
"Macrocyclic peptides have the potential to unlock new opportunities to develop oral treatment options for challenging therapeutic targets and broaden patient access," Dr. Dean Y. Li, president of Merck Research Laboratories, said in a statement.
The new method uses a suite of engineered enzymes to build the complex, ring-shaped molecule, a process called biocatalysis. This approach enables large-scale production that Merck says is not possible with traditional chemical synthesis, offering a more sustainable and efficient path to manufacturing. Enlicitide is designed to be a daily pill, a significant advantage over currently approved injectable PCSK9 inhibitors.
The development underpins Merck's strategy in the vast cardiovascular market, as the company's stock has surged nearly 34 percent over the past six months. With a market capitalization of $276 billion, the company is betting that the novel drug, if approved, can capture a significant share of the market for treating atherosclerotic cardiovascular disease, which causes 85 percent of all cardiovascular deaths globally.
The drug, a macrocyclic peptide, is designed to lower LDL cholesterol by binding to the PCSK9 protein. This prevents the protein from interacting with LDL receptors, leaving more receptors available to remove cholesterol from the blood. For over a decade, Merck scientists have been working on this class of molecules, which aim to provide the potency of biologic therapies in the form of an oral pill.
The company has invested in biocatalysis for over 25 years, developing novel enzymes to manufacture pharmaceuticals at scale. This publication provides a blueprint for producing other complex macrocyclic peptides, potentially unlocking a new class of oral medicines for difficult-to-drug targets.
This scientific advance is the latest in a series of positive developments for Merck. The company recently reported first-quarter earnings that beat analyst expectations and completed a $5.8 billion acquisition of Terns Pharmaceuticals to bolster its pipeline.
The manufacturing breakthrough for enlicitide significantly de-risks the path to commercial scale-up, a critical factor for a drug targeting a massive patient population. Investors will now watch for upcoming clinical trial data and subsequent regulatory filings as the next major milestones.
This article is for informational purposes only and does not constitute investment advice.
